Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple-drug cocktail takes on hard-to-treat head and neck cancer

NCT ID NCT06239220

Recruiting now Disease control Sponsor: Glenn J. Hanna Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immunotherapy. The goal is to see if this triple approach can shrink tumors and control the disease. Participants will receive all three treatments intravenously or by injection, and researchers will monitor for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PD-L1 t-haNK (modified immune cells), NAI (immune-stimulating protein), and cetuximab (targeted antibody)

What this could lead to

If successful, this combination could offer a new treatment option for patients with advanced head and neck cancer who have already tried immunotherapy.

What could go wrong

This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet known if it will be more effective than existing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA METASTATIC HEAD AND NECK CANCER METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA RECURRENT HEAD AND NECK CANCER RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact